Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Francesco PattiDepartment of Neurology, University of Catania, Catania, ItalyAbstract: Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient’s adherence to treatment, including the patient’s MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.Keywords: multiple sclerosis, adherence, compliance, interruption, adverse events, efficacy, tolerability, management
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200502 · Cited by 131
Cited by
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Recommendations for cognitive screening and management in multiple sclerosis care
Kalb, R., Beier, M., Benedict, R. H., Charvet, L., Costello, K., Feinstein, A., Gingold, J., Goverover, Y., Halper, J., Harris, C., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518803785 · Cited by 407
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Metadata
- Authors
- Patti, F.
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 4
- Pages
- 1
- ISSN
- 1177-889X (ISSN-L)
- OpenAlex
- W2080458330
- Cited by
- 170
- References
- 2
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. https://app.cochat.ai/papers/10.2147/ppa.s8230
- The paper
- Patti, F. (2010). Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence. https://doi.org/10.2147/ppa.s8230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.